[4] Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia.

[9][10][11] In November 2007, Schering-Plough acquired Organon BioSciences and veterinary pharmaceutical company Intervet from Akzo Nobel.

[14] In May 2020, Merck & Co. announced that Organon & Co. will be the name of "the pending spin-off of its women’s health, legacy products, and biosimilars businesses, which the company says is on track to be completed by the end of the first half in 2021.

A copy of the Information Statement sent to Merck shareholders was filed with the U.S. SEC on April 20, 2021, in a Form 10-12B/A, Exhibit 99.1 [16][17] In November 2021, the business announced it would acquire Forendo Pharma and its lead compound, a potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor.

During its period of independent operation, Organon developed a large number of compounds which were never adopted for medical use, but continue to be used for a variety of scientific research.

Organon was accused of selling its anti-depression medication Remeron at a discount to nursing home pharmacies (in order to encourage use), yet filing claims to Medicare for reimbursement at the full, undiscounted price.